公开(公告)号：US20240425498A1

公开(公告)日：2024-12-26

申请号：US18698137

申请日：2022-10-03

Applicant: FORX THERAPEUTICS AG

Inventor： Ulrich Luecking ,  Andreas Goutopoulos ,  Jin Tian ,  Sotirios Sotiriou ,  Luca Iacovino ,  Alena Freudenmann ,  Olivier Querolle

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/438 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  C07D519/00 ,  C07F9/6561

Abstract: The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, pharmaceutically acceptable salt or a prodrug thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as PARC inhibitors, and can be used in a method of treatment of a proliferative disorder, preferably of cancer.

公开(公告)号：US20250002491A1

公开(公告)日：2025-01-02

申请号：US18698169

申请日：2022-10-03

Applicant: FORX THERAPEUTICS AG

Inventor： Ulrich Luecking ,  Andreas Goutopoulos ,  Jin Tian ,  Sotirios Sotiriou ,  Luca Iacovino ,  Alena Freudenmann ,  Olivier Querolle

IPC: C07D471/04 ,  A61K31/496

Abstract: The present invention relates to a compound of formula (I) as PARC inhibitors for the treatment of proliferative disorders, such as e.g. cancer. Preferred compounds are e.g. N,N-dimethyl-4-(7-(N-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl) piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives, such as e.g. the present example 1, N,N-dimethyl-4-(7-(N-(1-methyl-cyclopropyl)sulfamoyl)-1-(6-methylpyridin-3-yl)imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide (II). Experimental data of PARC inhibition assays of exemplary compounds is provided.